Viral Eradication and Fibrosis Resolution in Post-Liver Transplant Cholestatic Hepatitis C Virus

TO THE EDITOR:
Cholestatic hepatitis (CH) is an extremely severe form of recurrent hepatitis C virus (HCV) after liver transplantation (LT) that is characterized by the rapid and early development of cholestasis and portal hypertension. Its spontaneous prognosis is extremely poor because it leads to graft failure and patient death in most cases if viral eradication is not achieved. (1) Although the prognoses of patients improve significantly after viral clearance, (2) (3) (4) (5) there is not information about how the rapid development of fibrosis in these patients responds to viral eradication.
Patients and Methods
PATIENTS
As described previously, we performed a cohort study in which we included all patients with recurrent HCV after LT who achieved sustained virological response (SVR) between 2001 and 2015 in our center, and who had paired liver biopsies before antiviral therapy and 12 months after SVR. (6) In the previous report, patients with CH were excluded. This particular population is the focus of the present report.
HISTOLOGICAL EVALUATION
A liver biopsy was performed before antiviral therapy and 12 months after SVR. CH was defined according to the modification of the International Liver Transplantation Society criteria proposed by Verna et al. (1) Post-SVR biopsies were staged and graded with the METAVIR classification. Patients with a biopsy sample size <10 mm and/or <6 portal tracts were excluded.
OTHER ASSESSMENTS
For patients in whom liver biopsies were obtained by a transjugular approach, a hepatic venous pressure gradient (HVPG) measurement was also obtained. In addition, since 2007, a liver stiffness measurement (LSM) with FibroScan (Echosens, France) is performed before antiviral therapy and 12 months after SVR. Finally, a fasting serum sample was obtained before treatment and 12 months after SVR and was kept at -808C to calculate the enhanced liver fibrosis (ELF) score (ADVIA Centaur, Siemens Healthcare Diagnostics, Tarrytown, NY). based in direct-acting antiviral (DAA) regimens. The regimens used differed according to the drugs approved in Spain, financial disposal, and compassionate and expanded-access programs. Treatment duration and RBV use was at the physician's discretion according to the European Association for the Study of the Liver guidelines when available.
ANTIVIRAL THERAPY
Results
PATIENTS
Thirteen patients with a confirmed diagnosis of CH who achieved SVR and with paired liver biopsies were considered. One patient was excluded due to a biopsy <10 mm, and thus, 12 patients were included. Table 1 shows the characteristics of the patients at baseline and at follow-up. To put these figures into perspective, during the study period 38 patients met the definition of CH and underwent antiviral treatment, with 17 (45%) achieving SVR. Four patients were not considered for this study for absence of follow-up biopsy.
HISTOLOGICAL OUTCOMES
All patients presented sinusoidal or pericellular fibrosis in baseline biopsy. The post-SVR follow-up biopsy showed the absence of fibrosis in 5 (42%) patients, F1 in 4 (33%), F2 in 1 (8%), and cirrhosis in the remaining 2 (17%) patients. Necroinflammatory grade at follow-up was A0 in 2 (17%) patients, A1 in 9 (75%) patients, and A2 in 1 (8%) patient. No patient presented with cholestasis or hepatocyte ballooning. Figure 1 illustrates representative biopsy samples of the same patient before treatment (Fig. 1A) and 12 months after SVR (Fig. 1B) .
HEMODYNAMIC ASSESSMENT
Nine (75%) patients had paired HVPG measurements before and after SVR. The median HVPG decreased from 8 (5-11.5) mm Hg at baseline to 4 (2-9.5) mm Hg 12 months after SVR (P 5 0.17). A total of 44% of patients presented with HVPG 10 mm Hg before antiviral therapy and 22% at follow-up (P 5 0.17). Individual changes in HVPG are depicted in Fig. 2A . 
ELF SCORE
Eleven (92%) patients had paired ELF measurements before and after SVR. The median ELF score changed from 13.5 (12.3-14.4) at baseline to 9.7 (9.3-11.2) at follow-up (P 5 0.003). Figure 2C shows individual changes in ELF score.
CLINICAL OUTCOMES
At treatment, 50% of patients were decompensated. When evaluated at follow-up, only 1 (8%) patient remained decompensated. Individual changes in bilirubin are shown in Fig. 2D . After a median follow-up of 16 (8-27) months, 92% of the patients remain alive, and no patient has undergone retransplantation. One patient died during follow-up due to complications of cirrhosis while awaiting a second graft.
Discussion
CH is the most dreaded form of HCV recurrence after LT. In a recent review, 16/17 patients diagnosed with this type of recurrence died or underwent retransplantation at a mean time of 8 months since diagnosis. (2) In contrast, the outcomes of patients with CH who were able to eradicate infection are clearly improved. Leroy et al. described 23 LT recipients with CH who underwent antiviral therapy with SOF and RBV or SOF and daclatasvir (DCV). (3) SVR was 96%, and not less importantly, there were no deaths or graft losses during the study period with most patients presenting a dramatic improvement in liver function and in clinical decompensations. Similarly, in a multicenter study in which only 10 patients met the definition for CH and were treated with the combination of SOF and RBV (with or without PEG-IFN), 8/10 patients achieved SVR at 12 weeks, and all of them were alive after completing follow-up (2 retransplanted). (4) Similar results have been recently shown by a multicenter Italian study that included 21 patients with CH. (5) It is important to highlight that the effect of viral eradication on liver histology, portal pressure, liver stiffness, or fibrosis biomarkers has been scarcely described.
Our data confirm the significant improvements shown by these studies and indeed go further because we have been able to show that viral eradication is accompanied by complete resolution of fibrosis in 42% of the patients. In fact, in only 17% of patients, the extremely rapid fibrotic process typical of this condition had a potentially significant impact, as 2/12 patients developed early cirrhosis despite viral eradication. One of the 2 patients with cirrhosis died due to complications of cirrhosis, while the other remains compensated. These marked histological improvements are accompanied by a decrease in HVPG and LSM, which were probably not statistically significant due to the sample size, whereas the changes in the ELF score were statistically significant. All these improvements merge together to finally result in a significant clinical benefit, with less progression to end-stage graft disease, higher patient and graft survival, and thus decreased organ utilization for retransplantation.
Studies like this may seem out-of-time, considering the high efficacy of antiviral therapy in patients awaiting LT. However, despite the efficacy and safety of DAAs in patients with cirrhosis, there are still a number of concerns regarding antiviral treatment in LT candidates. Due to these concerns, a proportion of wait-listed patients will still undergo LT with detectable serum HCV, and thus under the risk of developing CH. In addition, given the availability of DAAs, it is even more important to diagnose CH early because we now have a higher chance of SVR than in the interferon era. The opportunity to make a difference in clinical outcomes is thus now within our reach, whereas previously, even with timely diagnosis and treatment, prognosis was dismal.
A significant limitation of our study is the sample size. However, CH is an infrequent type of recurrence, and thus, all studies in this setting present this limitation. In fact, most manuscripts regarding CH are case reports or short series, and even in the case of multicenter studies, sample sizes are limited.
In conclusion, we show that viral eradication in patients with CH not only leads to improved clinical outcomes, but it also permits significant improvements in liver histology, including the absence of fibrosis in nearly half of the patients.
